PRTG

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Retrieved on: 
Wednesday, February 28, 2024

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.

Key Points: 
  • WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.
  • R&D costs increased slightly by approximately $0.1 million, or approximately 1%, from approximately $2.7 million in the Fiscal 2023 Quarter, to approximately $2.8 million in the Fiscal 2024 Quarter.
  • G&A expenses decreased by approximately $0.7 million, or approximately 35%, from approximately $2.0 million in the Fiscal 2023 Quarter, to approximately $1.3 million in the Fiscal 2024 Quarter.
  • The Company’s other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal 2024 Quarter, compared to approximately $0.6 million net expense during the Fiscal 2023 Quarter.

Paessler AG's Mike Gonzalez and Peter Campisi Recognized as 2024 CRN® Channel Chiefs

Retrieved on: 
Monday, February 5, 2024

CHICAGO, Feb. 5, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Mike Gonzalez and Peter Campisi, on its 2024 Channel Chiefs list.

Key Points: 
  • CHICAGO, Feb. 5, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Mike Gonzalez and Peter Campisi, on its 2024 Channel Chiefs list.
  • Each year, the prestigious CRN® Channel Chiefs list recognizes the IT vendor and distribution executives who are driving strategy and setting the channel agenda for their companies.
  • 2024 is the second consecutive year that Gonzalez has been named to the list, and the third for Campisi, for their impact on the channel.
  • The Channel Company is pleased to acknowledge these prominent channel leaders and looks forward to chronicling their achievements throughout the year."

Portage Biotech Reports Business and Strategic Update

Retrieved on: 
Thursday, January 4, 2024

The phase 1a dose escalation portion of the trial is enrolling quickly and there have been no safety signals of concern at the doses evaluated to date.

Key Points: 
  • The phase 1a dose escalation portion of the trial is enrolling quickly and there have been no safety signals of concern at the doses evaluated to date.
  • The company looks forward to presenting data from this portion of the trial at a conference later this year.
  • There is still much to learn about how to develop therapeutics for this target,” remarked Dr. Walters.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Retrieved on: 
Tuesday, November 28, 2023

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.

Key Points: 
  • WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
  • “The Company is focused on developing its two lead clinical programs and maximizing its resources given market conditions.
  • Portage completed a $6 million financing in October 2023 for continued clinical development, general corporate and working capital purposes.
  • R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180%, for the Fiscal 2024 Quarter from approximately $1.5 million in the Fiscal 2023 Quarter.

Paessler AG's PRTG OPC UA Server wins New Equipment Digest's Innovation Awards in Software & Computer Category

Retrieved on: 
Tuesday, November 28, 2023

CHICAGO, Nov. 28, 2023 /PRNewswire/ -- Paessler AG, the creator of technology monitoring software PRTG, has been selected as the New Equipment Digest (NED) Innovation Awards winner in the Software & Computer category for PRTG OPC UA Server, its product extension created specifically for the industrial/manufacturing industry.

Key Points: 
  • PRTG OPC UA Server is one of 15 products selected for prestigious industrial technology, tools and equipment award
    CHICAGO, Nov. 28, 2023 /PRNewswire/ -- Paessler AG , the creator of technology monitoring software PRTG , has been selected as the New Equipment Digest (NED) Innovation Awards winner in the Software & Computer category for PRTG OPC UA Server , its product extension created specifically for the industrial/manufacturing industry.
  • Paessler's PRTG OPC UA Server was one of 15 products selected for this year's awards.
  • "We are thrilled that New Equipment Digest readers voted for PRTG OPC UA Server to win the NED Innovation Award in the Software & Computer category," said David Montoya, Paessler AG's Global IoT Business Development Manager.
  • For more information about PRTG OPC UA Server, or other ways that PRTG helps industrial operations, visit https://www.paessler.com/prtg/extensions/prtg-opc-ua-server .

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023

These data build on previous results shared at the 2023 American Society of Clinical Oncology (ASCO) meeting in June and include new information on the novel pharmacology profile of PORT-2.

Key Points: 
  • These data build on previous results shared at the 2023 American Society of Clinical Oncology (ASCO) meeting in June and include new information on the novel pharmacology profile of PORT-2.
  • “We continue to see single agent activity of PORT-2 at the 3 and 9 mg/m2 dose.
  • Dr. Sumit K. Subudhi from the University of Texas MD Anderson Cancer Center presented the design of the ADPORT-601 trial.
  • Both posters will be added to the “Presentations & Publications” section of Portage’s website following the conference.

Paessler aligns new capabilities to provide MSPs with improved visibility of client environments across vertical markets

Retrieved on: 
Monday, October 30, 2023

MIAMI, Oct. 30, 2023 /PRNewswire/ -- Channel Futures MSP Summit – Booth 333 – Through recent acquisitions and internal product developments, Paessler AG, the creator of technology monitoring software PRTG,  has developed an even more robust strategy around its suite of solutions for MSPs to deliver more value to their end user customers. The company also has developed a diverse set of vertical industry specific sensors that allow MSPs to monitor environments that go beyond traditional IT to offer a specialized approach to proactive monitoring.

Key Points: 
  • The company also has developed a diverse set of vertical industry specific sensors that allow MSPs to monitor environments that go beyond traditional IT to offer a specialized approach to proactive monitoring.
  • Paessler's PRTG offers the data input across an MSPs customer portfolio and Qbilon enables automated up-to-date documentation of the provided information.
  • "End-user customers often times have separate environments that cannot offer visibility to each other, and have unique functionality that requires a specific tool to ensure uptime.
  • For more information about Paessler, visit the team at Channel Futures MSP Summit in booth #333.

When data creates knowledge: the combined analytical strength of Paessler PRTG and Qbilon

Retrieved on: 
Tuesday, October 10, 2023

NUREMBERG, Germany, Oct. 10, 2023 /PRNewswire/ -- With over 1,200 employees and 24 subsidiaries, the global IT and OT environment of the German engineering company KTR Systems GmbH has become increasingly complex and challenging to manage. With monitoring solutions like Paessler AG's PRTG already implemented, Qbilon enabled KTR Systems to have an automated bird's eye view of their IT and OT landscape. Paessler AG acquired the IT startup Qbilon from Augsburg, Germany, in early 2023, and the combined potential of both companies' software solutions proves to have great potential – best illustrated in the showcase of KTR Systems.

Key Points: 
  • With monitoring solutions like Paessler AG's PRTG already implemented, Qbilon enabled KTR Systems to have an automated bird's eye view of their IT and OT landscape.
  • "I see Qbilon as a strategic investment – because data on its own is just data, but Qbilon tells me what to do with it," said Olaf Korbanek, head of IT at KTR Systems.
  • While monitoring tools like Paessler PRTG offer the data input, Qbilon enables automated up-to-date documentation of the provided information.
  • For KTR Systems, PRTG's monitoring data functions  like a map, whereas Qbilon enables smart navigation through the complex landscapes.

Portage Biotech Announces $6.0 Million Registered Direct Offering

Retrieved on: 
Friday, September 29, 2023

The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $6.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of such securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement.
  • A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

Paessler AG announces acquisition of Swiss technology company ITPS AG

Retrieved on: 
Thursday, September 28, 2023

NUREMBERG, Germany, Sept. 28, 2023 /PRNewswire/ -- Paessler AG, a leading provider of IT, OT, and IoT monitoring solutions based in Nuremberg, Germany, announces the successful acquisition of ITPS Group, with subsidiaries in Switzerland, the Czech Republic, and Romania as well as business activities in India. This strategic development comes in the run-up to IT-SA 2023 and marks another step in Paessler's ambition to offer its customers a diversified range of individual features for any infrastructure and monitoring objective.

Key Points: 
  • ITPS, known for its software products under the name CORP-IT, has established itself in the IT industry through innovative solutions.
  • Prior to this strategic development, ITPS was a valued Paessler Alliance Partner & Paessler Gold Partner for many years.
  • "Our collaboration with Paessler has always been characterized by mutual trust and innovation," said Thomas Wächter, founder of ITPS AG.
  • During IT-SA 2023, Paessler will offer exclusive interviews on this acquisition in Hall 7, Booth 7-537.